<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093184</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-BIV-04-01</org_study_id>
    <nct_id>NCT00093184</nct_id>
  </id_info>
  <brief_title>Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI</brief_title>
  <official_title>A Study Evaluating the Safety and Efficacy of Bivalirudin in the Management of Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary PCI (BIAMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the benefit of bivalirudin in combination with&#xD;
      clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications&#xD;
      associated with early invasive management of patients presenting with an ST Elevation&#xD;
      Myocardial Infarction (STEMI) and undergoing primary PCI, while providing similar rates of&#xD;
      ischemic events when compared to published results of relevant trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date>December 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in bleeding complications</measure>
  </primary_outcome>
  <enrollment>300</enrollment>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiomax (bivalirudin) anticoagulant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients &gt;18 years of age.&#xD;
&#xD;
          2. Symptoms of STEMI for at least 30 min within previous 12 hours AND&#xD;
&#xD;
               -  ST-segment elevation in at least 2 contiguous leads or new Left Branch Bundle&#xD;
                  Block (LBBB), OR existing LBBB with positive troponin&#xD;
&#xD;
               -  Residual high grade stenosis and associated abnormalities in regional wall&#xD;
                  motion.&#xD;
&#xD;
          3. Planned primary PCI in native coronary vessel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed pregnancy&#xD;
&#xD;
          2. Fibrinolytic therapy - Any alteplase, reteplase, tenectoplase, or streptokinase within&#xD;
             the last 24 hours&#xD;
&#xD;
          3. Culprit lesion within SVG or bypass conduit&#xD;
&#xD;
          4. Dependency on renal dialysis&#xD;
&#xD;
          5. Administration of LMWH within 8 hours prior to PCI&#xD;
&#xD;
          6. Administration of abciximab within 7 days prior to PCI&#xD;
&#xD;
          7. Administration of eptifibatide or tirofiban within 12 hours prior to PCI&#xD;
&#xD;
          8. Warfarin MUST BE discontinued prior to procedure, and the INR must be ⎕1.5, or the&#xD;
             PT&lt;15,&#xD;
&#xD;
          9. Heparin. If heparin is administered in the ER as long as it is discontinued at least&#xD;
             30 minutes prior to procedure, OR ACT &lt;250, a patient may be enrolled. No clotting&#xD;
             measurements are required if patient received heparin ⎕30 minutes prior to the&#xD;
             initiation of bivalirudin.&#xD;
&#xD;
         10. Allergy to heparin or bivalirudin, or known sensitivity to any component of the&#xD;
             products&#xD;
&#xD;
         11. Allergy to aspirin, clopidogrel, or abciximab&#xD;
&#xD;
         12. Contraindication to abciximab&#xD;
&#xD;
         13. Angiomax within 24 hours prior to study drug administration&#xD;
&#xD;
         14. Neurosurgery with three months&#xD;
&#xD;
         15. Severe hypertension not adequately controlled by antihypertensive therapy at the time&#xD;
             of study entry (BP &gt;180/110 mm Hg)&#xD;
&#xD;
         16. Cardiogenic shock (SBP &lt;80 for &gt;30 min or a need for intravenous pressors)&#xD;
&#xD;
         17. Stroke within three months&#xD;
&#xD;
         18. Any hemorrhagic diathesis&#xD;
&#xD;
         19. Life expectancy &lt;1 year&#xD;
&#xD;
         20. Participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F Stella, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Care Centers of Illinois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Heart Care Research Foundation</name>
      <address>
        <city>Blue Island</city>
        <state>Illinois</state>
        <zip>60406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2006</verification_date>
  <study_first_submitted>October 4, 2004</study_first_submitted>
  <study_first_submitted_qc>October 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2004</study_first_posted>
  <last_update_submitted>February 8, 2006</last_update_submitted>
  <last_update_submitted_qc>February 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2006</last_update_posted>
  <keyword>ST-Segment Elevation</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>PCI</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

